Moderna Shares Slide 3% After FDA Refuses Updated COVID-19 Booster Approval
Moderna shares slid 3% in premarket trading after the FDA refused its application for an updated COVID-19 booster vaccine. The decision delays the company’s planned booster rollout and defers potential revenue into the next fiscal quarter.
1. FDA Declines Booster Approval
The FDA reviewed Moderna’s application for its updated COVID-19 mRNA booster and concluded that additional immunogenicity and safety data are needed before granting approval. This refusal halts the company’s plan to launch the next-generation booster ahead of the upcoming respiratory virus season.
2. Shares Slide in Premarket Trading
Moderna’s stock price fell roughly 3% in early trading following the announcement, reflecting investor concern over the lost near-term revenue opportunity. Trading volumes spiked as market participants adjusted positions in response to the regulatory setback.
3. Implications for Revenue and Pipeline
The delay pushes anticipated booster sales and related royalty income into a later quarter, potentially affecting Moderna’s full-year guidance. The company will now focus on gathering the required additional clinical data and resubmitting its application to the FDA.